7th TCR-Based Therapies Summit The Colonnade Hotel, Boston

The past few years for the TCR community have been dynamic. Approvals have signalled a viable path to commercialization, while a wave of company closures highlight the deep-rooted challenges in the current development processes. The message is clear: success is not guaranteed at approval. Addressing manufacturing costs, durability and long-term commercial viability is now mission critical for developers of TCR-based cell and biologic therapies.

Spanning the full therapeutic landscape, including TCR-T, TCR mimetics, TCR-TCEs and TCR bispecifics, the 7th TCR-Based Therapies Summit cuts through the noise to focus exclusively on the challenges most acutely impacting the TCR field today. Connect with and hear directly from senior leaders driving progress at the forefront of the field, including C-suite leaders at Immunocore, Immatics, T-knife Therapeutics, Anocca, Zelluna Immunotherapy, Enara Bio, Marengo Therapeutics, and 3T Biosciences.

With the foundations now in place, join us in empowering the community to shape a more durable, scalable, and commercially robust future for TCR-based therapies.